IDO1 and neoplasm: Inhibiting AHR, particularly alongside PD-1 blockade, counters this effect and slows tumor progression, suggesting a tailored immunotherapeutic strategy that combines AHR inhibition with checkpoint inhibitors to overcome resistance in IDO/TDO-high cancers [73].